Skip to content

Thymopentin

A 5-residue active fragment of the 49-residue thymic peptide thymopoietin, characterized in the late 1970s and 1980s as an immunomodulator with effects on T-cell maturation. Approved in Italy as Timunox and Sintomodulina for immunodeficiency states — both registrations have since been revoked — and still manufactured and sold in China today as a 10 mg injection for immune suppression caused by radiotherapy and chemotherapy. Its half-life in human plasma is about 30 seconds in vitro (Tischio 1979), which sounds disqualifying. The paper's own conclusion runs the other way, though: because the pentapeptide is active in vivo despite that, the authors inferred it “may rapidly trigger changes in responsive cells; sustained circulating levels may not be required for activity.”

DPreliminaryLimited Data
Last updated 19 citations
TL;DR

Thymopentin is five amino acids — Arg-Lys-Asp-Val-Tyr — cut from the middle of thymopoietin, the 49-residue thymic hormone Gideon Goldstein isolated in 1974 and first called thymin. Its half-life in human plasma is about 30 seconds, and the paper that measured it argued this was beside the point: the peptide works in vivo anyway, so it probably triggers responsive cells quickly rather than needing sustained levels. Every dosing schedule it has ever had rests on that reading. The two conditions most often attached to it, atopic dermatitis and rheumatoid arthritis, were trial indications and appear on neither Italian label — what it was actually licensed for in Italy, as Timunox and Sintomodulina, was immunodeficiency, and both registrations have since been revoked. The trials themselves were better than its reputation: significantly better than placebo in active rheumatoid arthritis, significantly better at 12 weeks in severe atopic dermatitis, and in 352 zidovudine-treated HIV patients, two AIDS or death events on thymopentin against ten on placebo in the stratum with prior AZT exposure — though that HIV programme was sponsor-run with the discoverer as first author. It is also not the discontinued relic it is usually described as. Thymopentin injection is an approved, manufactured prescription drug in China, sold as 10 mg ampoules for immune suppression caused by chemotherapy and radiotherapy, and most research on it now comes from there. A 2026 case report of thymopentin-induced myasthenia gravis is the one genuine safety signal, and it is mechanistically apt: thymopoietin was discovered through its effects on neuromuscular transmission.

What is Thymopentin?

Thymopentin (TP-5, sequence Arg-Lys-Asp-Val-Tyr) is a 5-residue active fragment of thymopoietin, the 49-residue thymic peptide isolated by Gideon Goldstein, who reported it in Nature in 1974 and whose group at Memorial Sloan Kettering went on to synthesise the active pentapeptide, reported in Science in June 1979 (PMID 451537). He is a different scientist from Allan L. Goldstein, the co-discoverer of the thymosins, who worked at Albert Einstein College of Medicine and later George Washington University — the two are routinely confused, and thymopoietin and TP-5 belong to Gideon. The TP-5 sequence corresponds to residues 32-36 of thymopoietin and was shown to retain the immunomodulatory activity of the parent peptide in prothymocyte and B-lineage differentiation assays — in the founding paper it induced murine prothymocytes to differentiate into thymocytes while inhibiting differentiative induction of B-lineage cells — making it a tractable synthetic active counterpart to the larger natural-extract preparations. The 1979 Tischio paper in International Journal of Peptide and Protein Research (PMID 395119) characterized TP-5's plasma half-life as about 30 seconds in human plasma in vitro — while explicitly arguing that this need not be a limitation, since the peptide is active in vivo and may act by rapidly triggering responsive cells rather than by sustained exposure — and subsequent decades of work explored TP-5's effects on T-cell maturation and immune function across various disease contexts. Thymopentin reached the market in Italy under two brands — Timunox, held by Cilag and later Janssen-Cilag, and Sintomodulina from Italfarmaco — and it is worth being precise about what they were licensed for, because the peptide's reputation and its label have drifted apart. The authorised indications were immunodeficiency: congenital thymic aplasia and the primary immunodeficiencies (DiGeorge, Nezelof, SCID, ataxia-telangiectasia), secondary immunodeficiency with chronic or recurrent infection, surgical or radiation damage to the thymus, complications of chemotherapy and radiotherapy, and use as a vaccine adjuvant. Atopic dermatitis and rheumatoid arthritis, the two conditions most often named in connection with thymopentin, were trial indications rather than approved ones and appear on neither Italian label. The rheumatoid arthritis evidence base rests principally on the Malaise 1985 Lancet double-blind placebo-controlled trial of slow-IV TP-5 in active RA (PMID 2858708); the atopic dermatitis evidence base rests on Leung 1990 J Allergy Clin Immunol (PMID 2185294) reinforced rather than offset by the Stiller 1994 JAAD double-blind placebo-controlled adjunctive study (PMID 8157786), in which thymopentin-treated patients had significantly greater improvement than placebo at 12 weeks with no thymopentin-related adverse events; and a pre-HAART-era HIV chapter includes the Conant 1992 AIDS CD4+ maintenance trial (PMID 1361746) and Goldstein 1995 JAIDS AZT-adjunct trial (PMID 7859140) — the latter with Gideon Goldstein, who discovered thymopoietin, as first author — writing from the Immunobiology Research Institute in Annandale, New Jersey, which is also the registered sponsor of every thymopentin HIV trial on ClinicalTrials.gov. The HIV evidence base is in other words sponsor-run work led by the molecule's discoverer, which is a reason to read it carefully rather than a mark of authority. All of these were subsequently displaced by more effective disease-specific therapies (methotrexate + biologic DMARDs for RA, dupilumab and JAK inhibitors for AD, combination antiretroviral therapy for HIV). The Singh 1998 Immunology Research paper (PMID 9638477) consolidated thymopentin and the related splenopentin as immunomodulators, framing the pentapeptide approach within the broader thymic-peptide therapy landscape. The pairing is a family resemblance rather than a functional equivalence: splenopentin differs by a single residue, Glu for Asp at position 34, and the founding comparison between them was titled for their contrasting activities — thymopentin affects neuromuscular transmission and pushes T-precursor differentiation while inhibiting B-lineage induction, where splenopentin does neither of the first two and induces both lineages. The Bräuer 1993 Agents and Actions paper (PMID 8317333) extended the work to thymic and splenic peptide effects in antigen-induced arthritis. In the West the molecule did fade: both Italian registrations now carry revoked status, no FDA approval was ever obtained, and the indications thymopentin was trialled for were taken by better drugs — combination antiretroviral therapy for HIV, methotrexate plus biologic DMARDs for rheumatoid arthritis, dupilumab and the JAK inhibitors for atopic dermatitis. It would be wrong, though, to call thymopentin a discontinued historical compound, which is how it is usually described. It is a currently marketed prescription drug in China, where thymopentin injection (胸腺五肽) is made by several manufacturers under NMPA approval numbers including 国药准字 H20061226, supplied as 1 ml of 10 mg, and indicated for immune suppression in cancer patients undergoing radiotherapy or chemotherapy. The contemporary clinical and preclinical literature is correspondingly active rather than dormant.

What Thymopentin Is Investigated For

Thymopentin is a research-and-historical-clinical-agent topic, not a contemporary mainstream therapy. The 5-residue Arg-Lys-Asp-Val-Tyr peptide retains the immunomodulatory activity of the parent thymopoietin (the 49-residue thymic peptide isolated by Gideon Goldstein). The historical clinical translation included limited use in atopic dermatitis, rheumatoid arthritis, and chronic immune dysfunction in some European and Asian markets (notably as Timunox), but did not reach FDA approval and has been substantially superseded by the modern biologic immunotherapy class. The 1998 Singh Immunology Research review (PMID 9638477) is the standard reference framing thymopentin and splenopentin as immunomodulators within the broader thymic-peptide therapy concept. The short plasma half-life (Tischio 1979 PMID 395119) was a practical limitation requiring frequent dosing — typically subcutaneous administration multiple times per week. As of 2026 thymopentin is not FDA-approved for any indication and its Italian registrations have been revoked, but it remains an approved, manufactured and prescribed drug in China for chemotherapy- and radiotherapy-induced immune suppression, and the research literature is active — recent work covers thymic rejuvenation and T-cell reprogramming in tumour immunity, combination with oncolytic adenovirus, macrophage function in sepsis, and several chemistry programmes aimed squarely at the 30-second half-life. Alongside that, it is sold through research-channel sources for laboratory use with none of the quality control an approved product carries.

5-residue active fragment of thymopoietin with immunomodulatory effects on T-cell maturation
Moderate70%
Historical investigational agent for atopic dermatitis, rheumatoid arthritis, and chronic immune dysfunction
Preliminary30%
Sold as Timunox in some markets but not FDA-approved
Moderate70%
Still an approved, manufactured prescription drug in China for chemotherapy- and radiotherapy-induced immune suppression
Moderate70%

History & Discovery

Thymopentin is the distilled end of a hunt that began with a whole gland. In January 1974 Gideon Goldstein published the isolation of a polypeptide hormone from bovine thymus in Nature, under a name that did not survive: he called it thymin. The label collided with thymine, the DNA base, and the molecule was subsequently renamed thymopoietin — which is why the founding citation and the molecule's modern name do not match, a small trap for anyone tracing the literature backwards. Thymopoietin turned out to be 49 residues long and to do something specific enough to be worth chasing: it drove prothymocytes to become thymocytes while blocking the equivalent induction in B-lineage cells. The reduction came five years later. Working at Memorial Sloan Kettering with Scheid, Boyse, Schlesinger and Van Wauwe, Goldstein synthesised residues 32-36 of the parent hormone — arginyl-lysyl-aspartyl-valyl-tyrosine — and reported in Science on 22 June 1979 that five amino acids reproduced the full hormone's signature behaviour, including the paired induction-and-inhibition that the authors noted was "presently unique to the parent molecule thymopoietin." In athymic mice the pentapeptide also reduced the elevated autologous rosette-forming cells in the spleen. Their closing line — that the readily synthesised fragment "might serve as a therapeutic substitute for thymopoietin" — is the origin of everything the molecule later became. A naming note worth making once, because the literature of this period is genuinely confusing: Gideon Goldstein, of thymopoietin and TP-5, is a different scientist from Allan L. Goldstein, of Albert Einstein College of Medicine and later George Washington University, who co-discovered the thymosins. Thymic peptide reviews conflate them routinely. The pharmacokinetics arrived in the same year as the synthesis and looked like a death sentence. Tischio's 1979 measurement put the pentapeptide's half-life in human plasma at roughly 30 seconds in vitro. The paper itself argued the opposite of the obvious conclusion — since the peptide works in vivo regardless, the authors inferred it "may rapidly trigger changes in responsive cells" and that "sustained circulating levels may not be required for activity." The clinical programme was built on that reading, and the dosing that followed — roughly 50 mg given two or three times a week rather than continuously — only makes sense if it is correct. Clinically, thymopentin was developed by Cilag and Janssen and sold as Timunox, and the trials went wherever immune dysfunction could be found. Malaise's double-blind placebo-controlled study of slow intravenous TP-5 in active rheumatoid arthritis reached the Lancet in 1985. Atopic dermatitis produced Leung's 1990 Journal of Allergy and Clinical Immunology report and Stiller's 1994 double-blind placebo-controlled adjunctive trial in the Journal of the American Academy of Dermatology. And in the pre-HAART years the molecule was pushed hard at HIV: Conant's 1992 CD4 maintenance trial in AIDS, then a zidovudine-adjunct trial in 1995 with Gideon Goldstein himself as first author, two decades after he had isolated the parent hormone. What ended thymopentin was not a safety finding or a failed trial but the arrival of drugs that did the same jobs much better. Combination antiretroviral therapy took HIV, methotrexate plus biologic DMARDs took rheumatoid arthritis, and dupilumab and the JAK inhibitors took atopic dermatitis — each of them targeting a defined molecule rather than nudging T-cell maturation in general. A broad-spectrum immunomodulator with a 30-second half-life had little to offer against that, and in the West the molecule receded — the Italian registrations were eventually revoked and no FDA approval was ever obtained. The ending is only Western, though. Thymopentin was picked up in China, where it is still approved, still manufactured by several companies and still prescribed to cancer patients through chemotherapy, and where most of the research published about it now originates.

How It Works

Thymopentin is a tiny 5-amino-acid piece of a thymus protein that helps T-cells mature properly. It was discovered in the 1970s and used as a drug in some countries (sold as Timunox) for things like atopic dermatitis and rheumatoid arthritis, but it never got FDA approval in the U.S. The problem is that the peptide breaks down very quickly in the body, so you have to inject it several times a week, and the modern biologic drugs that target specific immune molecules (TNF inhibitors, IL-6 inhibitors, dupilumab, etc.) work much better for the same conditions. In the West thymopentin is now mostly a historical peptide, but it never actually went away — it is still an approved, manufactured prescription drug in China, used mainly to support the immune system of cancer patients going through chemotherapy or radiotherapy.

Thymopentin (TP-5) is a 5-residue peptide (Arg-Lys-Asp-Val-Tyr) corresponding to residues 32-36 of the 49-residue thymopoietin precursor. The molecule came from Gideon Goldstein's laboratory — he isolated thymopoietin and reported it in Nature in 1974, and his group at Memorial Sloan Kettering synthesised the pentapeptide, published in Science in 1979. This is a different scientist from Allan L. Goldstein of Albert Einstein College of Medicine and later George Washington University, who co-discovered the thymosins; the two names are constantly conflated in writing about thymic peptides in the 1970s. Thymopoietin itself was characterized as a thymic peptide with effects on T-cell maturation distinct from thymosin alpha-1 and other thymic peptides — and the TP-5 active fragment was shown to retain the principal activity of the parent hormone in prothymocyte differentiation, B-lineage inhibition and athymic-mouse rosette assays. The 1979 Tischio paper in International Journal of Peptide and Protein Research (PMID 395119) characterized TP-5's short plasma half-life — a key practical limitation that has constrained therapeutic translation throughout the molecule's commercial history. The immunomodulatory mechanism includes effects on T-cell maturation, modulation of T-cell function in immune dysregulation contexts, and effects on the cytokine production profile of activated immune cells. The mechanism is broad-spectrum rather than specifically targeted, contrasting with the modern biologic immunotherapy class that targets specific cytokines or receptors. The Singh 1998 Immunology Research review (PMID 9638477) consolidated thymopentin and the related splenopentin as immunomodulators within the broader thymic-and-splenic peptide therapy concept. The Bräuer 1993 Agents and Actions paper (PMID 8317333) extended the work to thymic and splenic peptide effects in antigen-induced arthritis. The clinical translation of thymopentin reached limited commercial use in some markets through Cilag/Janssen's Timunox preparation, with applications in chronic immune dysfunction including atopic dermatitis, rheumatoid arthritis, and immunodeficiency states. The dosing regimen (typically 50 mg subcutaneously three times weekly) reflected the short plasma half-life and the broad-spectrum immunomodulator mechanism. The clinical efficacy was modest by modern biologic-immunotherapy standards, and the FDA approval was never obtained. The Menzaghi 1996 Physiology and Behavior paper (PMID 8840897) characterized IRI-514, a synthetic peptide analog of thymopentin, in stress-response models — extending the molecule's research footprint beyond pure immunomodulation into broader behavioral and stress-response biology.

Evidence Snapshot

Overall Confidence35%

Human Clinical Evidence

Better than the page used to imply, and mostly unread. Four controlled trials reported positive results that are rarely quoted. Malaise 1985 in the Lancet found thymopentin significantly better than placebo at reducing tenderness, joint swelling, severity of pain on waking and disease activity in active rheumatoid arthritis. Stiller 1994 found significantly greater improvement than placebo at 12 weeks in severe atopic dermatitis. Conant 1992 found a greater area under the CD4 percentage curve in asymptomatic HIV patients (P = 0.03) with no difference in symptomatic ones. And Goldstein 1995, in 352 zidovudine-treated patients, found in the stratum with more than six months of prior AZT that two AIDS or death events occurred on thymopentin against ten on placebo (p = 0.024), and three ARC, AIDS or death events against eighteen (p = 0.001) — a clinical-endpoint result, not a surrogate one, though the second stratum showed no benefit and the whole HIV programme was sponsor-run with the discoverer as first author. Modern clinical use is Chinese: a 2025 retrospective cohort of 100 peritoneal dialysis patients reported a lower infection risk (HR 0.54, 95% CI 0.30-0.95; P = 0.034) while finding no change in CD3, CD4 or CD8 counts or the CD4/CD8 ratio. A Phase 3 trial in hepatocellular carcinoma after resection (NCT00460681, Fudan University, n=220) was registered in 2007 and has never reported.

Animal / Preclinical

Substantial historical literature. Goldstein's research program through the 1970s and 1980s, plus follow-up work by Singh, Bräuer, Menzaghi, and others through the 1990s and 2000s, characterized thymopentin's immunomodulatory effects across multiple animal models of immune dysfunction, autoimmune disease, and stress response.

Mechanistic Rationale

Moderate. The immunomodulatory mechanism is established at the cell biology level, and the active-fragment relationship to thymopoietin is well characterized. The broad-spectrum immunomodulator framework has been substantially superseded by modern targeted biologic immunotherapy in clinical relevance terms.

Research Gaps & Open Questions

What the current literature has not yet settled about Thymopentin:

  • 01Whether the 2026 myasthenia gravis case report represents a real class risk. The temporal association across repeated courses is suggestive and the mechanism is plausible given thymopoietin's original characterisation through neuromuscular transmission, but a single case cannot establish incidence, and no pharmacovigilance signal has been published from the Chinese market where most current exposure occurs.
  • 02What the Chinese clinical experience actually shows. Thymopentin has been prescribed there for roughly two decades, which is a large accumulated exposure, but the published clinical evidence is dominated by retrospective cohorts rather than randomised trials — and the one 2025 cohort reporting a lower infection rate in dialysis patients found no accompanying change in CD3, CD4 or CD8 counts, leaving the mechanism of any benefit unexplained.
  • 03Why the Fudan University Phase 3 trial in hepatocellular carcinoma after curative resection (NCT00460681, n=220, disease-free survival at three years) has never reported. It was registered in 2007 with an estimated completion of 2012 and the registry record has not been updated since 2007.
  • 04Whether engineering around the 30-second half-life changes anything clinically. Several groups have now produced stabilised forms — host-guest encapsulation, molecular hybridisation, PEGylated niosomes for oral delivery, fatty-acid modification — but the original pharmacokinetic paper argued that sustained levels are not required for activity, so extending exposure may not improve on the existing regimen and nobody has tested whether it does.
  • 05Modern controlled clinical trials of thymopentin against current standard-of-care biologic immunotherapy in atopic dermatitis, rheumatoid arthritis, or other immune-dysfunction indications
  • 06Characterization of any niche clinical role thymopentin might retain in the modern targeted-immunotherapy landscape
  • 07Long-term safety profile of contemporary thymopentin administration if any clinical pathway were revisited

Forms & Administration

Thymopentin is an injectable peptide and has never had an oral form, although PEGylated niosome work aimed at oral delivery has been published. The Italian labels carried three different regimens depending on indication, not the single one usually quoted: 50 mg subcutaneously three times weekly for three to six weeks in secondary immunodeficiency and after chemotherapy or radiotherapy; 0.5 to 1 mg/kg daily intramuscularly or subcutaneously for two weeks and then two to three times weekly in primary immunodeficiency; and 50 mg by slow intravenous injection in 10 ml of saline over ten minutes in autoimmune disease, which is the route and regimen the 1985 rheumatoid arthritis trial used. The currently marketed Chinese product is a different strength again, 10 mg per ampoule, and contemporary Chinese studies dose 10 mg rather than 50 mg. Synthetic thymopentin is also sold by research-chemical suppliers for laboratory use, with no quality control over identity, purity or sterility.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

Two different strengths in two different eras: 50 mg per injection in the Italian labels and the Western trials, and 10 mg per ampoule in the currently marketed Chinese product and in all contemporary Chinese studies.

Frequency

Depends entirely on indication: three times weekly for three to six weeks in secondary immunodeficiency, daily weight-based dosing then two to three times weekly in primary immunodeficiency, and 50 mg by slow intravenous injection for autoimmune disease. The atopic dermatitis trial dosed daily.

Timing Considerations

No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.

Protocol Notes

The figure that circulates for thymopentin — 50 mg, two or three times a week, subcutaneously — is real but is only one of four regimens the Italian labels carried, and it is not the dose used anywhere the drug is currently sold. It is worth understanding why the schedule looks the way it does. The pentapeptide's measured half-life in human plasma is about 30 seconds in vitro, so a regimen dosed every few days makes no sense at all on exposure grounds. It was built on the inference drawn in the original pharmacokinetic paper: that the peptide acts by rapidly triggering responsive cells rather than by maintaining a circulating level, so sustained exposure is not required for activity. Every thymopentin protocol ever used rests on that reading being right. The route varied by indication: slow intravenous injection in 10 ml of saline for autoimmune disease, intramuscular or subcutaneous weight-based dosing for primary immunodeficiency, subcutaneous for secondary immunodeficiency and after chemotherapy. There is no contemporary approved product in any Western market, which means no Western prescribing information and nothing to check a vendor's suggested protocol against. The one current approved label, in China, specifies a 10 mg product for a single indication — immune suppression from radiotherapy and chemotherapy in cancer patients — and is written in Chinese for prescribers there. Research-channel material is unregulated for identity, purity and sterility, and the historical regimen was administered under medical supervision for diagnosed conditions — neither of which describes self-administration.

Thymopentin is not FDA-approved for any indication. The figures above are a record of what was given in historical clinical programmes under medical supervision, not a protocol to follow.

Common Questions

What is thymopentin?

Thymopentin (TP-5) is a 5-residue active fragment of the 49-residue thymic peptide thymopoietin. The sequence corresponds to residues 32-36 of thymopoietin (Arg-Lys-Asp-Val-Tyr) and retains the immunomodulatory activity of the parent peptide in prothymocyte and B-lineage differentiation assays. It was developed as a tractable synthetic active counterpart to the larger natural-extract thymic preparations, with applications explored in chronic immune dysfunction, atopic dermatitis, and rheumatoid arthritis. It has been used clinically in some markets (sold as Timunox) but not in the U.S. — no FDA approval has been obtained.

Is thymopentin still used clinically?

Yes, in China, which is the part most accounts leave out. Thymopentin injection is an approved NMPA product there, made by several manufacturers under approval numbers including 国药准字 H20061226, supplied as 10 mg ampoules and indicated for immune suppression in cancer patients receiving radiotherapy or chemotherapy. Contemporary Chinese clinical studies use it in that setting and others, including a 2025 cohort of a hundred peritoneal dialysis patients. In the West the picture is the opposite: thymopentin reached the market in Italy as Timunox from Cilag and Janssen-Cilag and as Sintomodulina from Italfarmaco, licensed for immunodeficiency rather than for the dermatitis and arthritis indications it is usually associated with, and both registrations are now recorded as revoked. It was never FDA-approved. What displaced it in the West was the arrival of drugs that treated the same conditions better — biologic DMARDs and JAK inhibitors for rheumatoid arthritis, dupilumab and the JAK inhibitors for atopic dermatitis, combination antiretroviral therapy for HIV — against which a broad-spectrum immunomodulator with a 30-second half-life had little to offer.

How is thymopentin different from thymosin alpha-1?

Both are immunomodulatory peptides from the broader thymic-peptide family characterized in the 1970s — the thymosins by Allan L. Goldstein, thymopoietin and TP-5 by Gideon Goldstein — but they are distinct molecules with different sequences, biosynthetic origins, and clinical positioning. Thymopentin is a 5-residue active fragment of the 49-residue thymopoietin precursor. Thymosin alpha-1 (TA-1, thymalfasin, Zadaxin) is a 28-residue peptide derived from prothymosin alpha and approved in 35+ countries (not the U.S.) for hepatitis B and as adjunct in cancer immunotherapy. Thymosin alpha-1 has the more substantial international clinical experience and the more contemporary commercial presence; thymopentin is more of a historical and research-tier compound now. Both work as immunomodulators of T-cell maturation and function, with overlapping but not identical pharmacology.

Is thymopentin available in the United States?

Not as an FDA-approved drug. Thymopentin has not been FDA-approved for any indication in the U.S. and is not commercially available through licensed pharmacies. Some research-chemical and grey-market sources sell synthetic thymopentin for laboratory use, but consumer-research-channel use lacks FDA approval, validated dosing protocols, or human safety data appropriate for medical decision-making. Anyone considering thymopentin for any indication should engage with the honest framing — historical immunomodulatory peptide with limited international clinical experience, no FDA approval, no contemporary mainstream commercial development, no validated consumer-research-channel positioning.

Who Thymopentin Is NOT For

Contraindications
  • •Known hypersensitivity to thymopentin — one of only two contraindications the approved Chinese label states.
  • •Patients in the early period after organ transplantation who require immunosuppression — the label's other stated contraindication, and the clearest one: stimulating T-cell function works directly against the goal of preventing graft rejection.
  • •Myasthenia gravis or a history of it, and arguably any patient with neuromuscular symptoms on treatment. This is not on either label, but it follows from the 2026 case report and from the fact that thymopoietin was originally characterised through its effects on neuromuscular transmission.
  • •Autoimmune disease deserves a note rather than a blanket contraindication. Broad immunomodulation could in principle destabilise disease course, but the Italian label listed autoimmune disease as an adjunct indication with its own intravenous regimen, and the Chinese label cites rheumatoid arthritis and lupus among reported uses — so the historical regulatory position was the opposite of a prohibition.
  • •Patients with active malignancy — immune-system modulation could alter cancer biology unpredictably
  • •Pregnancy and lactation — limited safety data
  • •Patients seeking validated immunotherapy for diagnosed conditions should engage with modern targeted biologics rather than historical broad-spectrum immunomodulators

Drug & Supplement Interactions

Thymopentin has a thin but real interaction record rather than none at all. The approved Chinese label carries an interactions section stating that it has been co-administered with many commonly used drugs, including interferon, anti-inflammatories, antibiotics and hormones, without reported problems — which is a reassurance rather than a study. The one genuinely informative point is mechanistic: as a pentapeptide cleared by peptidases rather than hepatic oxidation, thymopentin would not be expected to disturb cytochrome-mediated metabolism, and a randomised study in the related diacetyl-splenopentin programme found no effect on caffeine clearance, the classic probe for that pathway. The interaction that does matter is pharmacodynamic and runs in the obvious direction. Thymopentin is given to restore T-cell function; immunosuppressive regimens exist to suppress it. Concurrent use after transplantation is contraindicated on the label for exactly this reason, and combination with modern biologic immunotherapy, checkpoint inhibitors or JAK inhibitors is uncharacterised and could plausibly oppose or amplify the intended effect.

Safety Profile

Safety Information

Common Side Effects

Injection-site reactions — the only finding in 12-month repeat-dose toxicology in rats and dogs at up to 80 mg/kg/dayNausea, fever, dizziness, chest tightness and weakness, listed as occasional on the approved Chinese label, with somnolence in a few patientsTransient rises in ALT reported in patients with chronic hepatitis BGenerally well-tolerated across the controlled trials, including Stiller 1994, which recorded no thymopentin-related adverse events

Cautions

  • • Not FDA-approved for any indication in the U.S.
  • • No validated consumer-research-channel dosing protocol
  • • A 2026 case report describes myasthenia gravis arising in a patient on intermittent thymopentin for triple-negative breast cancer, with anti-acetylcholine-receptor and anti-titin antibodies and no thymoma, and a consistent temporal association across repeated courses. This is a single case, but it is mechanistically coherent: thymopoietin, the parent hormone, was isolated in the first place while studying effects on neuromuscular transmission
  • • Pregnancy and lactation — limited safety data
  • • Compounded thymopentin in research-chemical channels has no validated clinical use and no quality-controlled reference product

What We Don't Know

Long-term safety of chronic thymopentin administration is incompletely characterized. The historical clinical experience in Timunox-marketed contexts produced a generally favorable tolerability profile, but the dataset is limited compared to modern biologic immunotherapy and has not been independently replicated to contemporary evidence standards. The molecule's positioning relative to modern targeted immunotherapy is unfavorable — biologic drugs targeting specific cytokines (TNF, IL-6, IL-17, IL-23, IL-4Rα, JAK pathway, etc.) have substantially displaced the broad-spectrum immunomodulator class that thymopentin represents.

Myths & Misconceptions

Myth

Thymopentin is FDA-approved for immune support.

Reality

It is not. Thymopentin has not been FDA-approved for any indication. The historical commercial availability was limited to some non-U.S. markets (Timunox in Europe and Asia) and has substantially declined as modern targeted biologic immunotherapy has displaced the broad-spectrum immunomodulator class.

Myth

Thymopentin is a discontinued drug that nobody uses any more.

Reality

Half right, and the half that is wrong is the larger one. In the West it is genuinely finished: both Italian registrations, Timunox and Sintomodulina, are recorded as revoked, and the FDA never approved it. But thymopentin injection is an approved NMPA product in China, made by several manufacturers under approval numbers including 国药准字 H20061226, supplied as 10 mg ampoules and prescribed for immune suppression in cancer patients having radiotherapy or chemotherapy. Most thymopentin research published in the last few years comes from there, including a 100-patient dialysis cohort, oncology combination work and several chemistry programmes attacking the half-life problem.

Myth

Thymopentin was approved as a treatment for atopic dermatitis and rheumatoid arthritis.

Reality

Those are the two conditions most often attached to thymopentin, and neither appears on either Italian label. They were trial indications. What the drug was actually licensed for was immunodeficiency — congenital thymic aplasia, the primary immunodeficiencies such as DiGeorge and Nezelof syndrome, secondary immunodeficiency with recurrent infection, thymic damage from surgery or radiation, and the complications of chemotherapy and radiotherapy. The confusion matters because it makes the evidence look thinner than it is: the dermatitis and arthritis trials were real and positive, they were simply never the basis of the registration.

Myth

Thymopentin is a contemporary first-line therapy for atopic dermatitis or rheumatoid arthritis.

Reality

It is not. Modern atopic dermatitis treatment is led by biologic drugs targeting Th2 inflammation (dupilumab, tralokinumab, lebrikizumab) and JAK inhibitors. Modern rheumatoid arthritis treatment is led by methotrexate plus biologic DMARDs (TNF inhibitors, IL-6 inhibitors, B-cell depletion, T-cell costimulation blockade) and JAK inhibitors. Thymopentin is a historical broad-spectrum immunomodulator that has been substantially superseded by these targeted therapies.

Myth

Buying thymopentin from research-channel vendors gives you a clinically validated immunomodulator.

Reality

It does not. Research-chemical and grey-market thymopentin is not the FDA-approved or contemporary-clinical-use product. Anyone with diagnosed immune-dysfunction conditions should engage with modern targeted immunotherapy under medical care rather than research-channel historical peptides.

Published Research

19 studies

Thymopentin enhances adenoviral oncolytic therapy by regulating macrophages and CD8(+) T cells

PreclinicalPMID: 41840011

Thymopentin-Induced Myasthenia Gravis: A Case Report Highlighting Clinical Vigilance.

Balkan Medical Journal 2026 — the first real safety signal in this molecule's literature, and mechanistically more plausible than a single case usually is. A 75-year-old woman receiving intermittent thymopentin for triple-negative breast cancer developed myasthenia gravis, with anti-acetylcholine-receptor and anti-titin antibodies and no thymoma on imaging, across repeated courses from 2019. The authors concluded that thymopentin may trigger or exacerbate myasthenia gravis in cancer patients with pre-existing immune dysregulation. What makes it worth taking seriously is the history: thymopoietin, the parent hormone, was isolated in the first place during work on effects of thymic extracts on neuromuscular transmission.

Case ReportPMID: 41504129

Thymopentin Enhances Antitumor Immunity Through Thymic Rejuvenation and T Cell Functional Reprogramming

PreclinicalPMID: 41153776

Effectiveness and safety of thymopentin for infection prophylaxis in peritoneal dialysis patients: a retrospective cohort study

BMC Nephrology 2025 — the clearest picture of what contemporary thymopentin use actually looks like, which is Chinese, 10 mg rather than 50 mg, and outside oncology. A hundred peritoneal dialysis patients were dosed 10 mg subcutaneously daily for five days and then three times weekly for twenty-three weeks. Multivariate analysis found a lower infection risk, hazard ratio 0.54 (95% CI 0.30-0.95, P = 0.034). The honest caveat is in the same abstract: no significant change was seen in CD3, CD4 or CD8 T-cell counts or in the CD4/CD8 ratio, so whatever produced the clinical signal was not visible in the immune parameters the drug is supposed to move.

Clinical StudyPMID: 41023915

Entire Encapsulation of Thymopentin by Extended Biphen[3]arene Carboxylate for Improving Plasma Stability

PreclinicalPMID: 39860184

Molecular hybridization modification improves the stability and immunomodulatory activity of TP5 peptide

PreclinicalPMID: 39588365

Thymopentapeptide Affects T-Cell Subsets by Modulating the Flora of the Skin Surface to Alleviate Psoriasis

PreclinicalPMID: 38984208

Thymopentin plays a key role in restoring the function of macrophages to alleviate the sepsis process

PreclinicalPMID: 38048668

Thymopentin and splenopentin as immunomodulators. Current status

ReviewPMID: 9638477

IRI-514, a synthetic peptide analogue of thymopentin, reduces the behavioral response to social stress in rats

Original ResearchPMID: 8840897

The effects of immunomodulatory thymic and splenic peptides and cyclosporin A on antigen-induced arthritis in the rat

Original ResearchPMID: 8317333

A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis

Clinical TrialPMID: 8157786

Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial

Goldstein G and colleagues (thymopoietin discoverer as first author), Journal of Acquired Immune Deficiency Syndromes 1995. Double-blind placebo-controlled trial of TP-5 as adjunct to AZT in asymptomatic HIV-infected subjects. The follow-up HIV study extending the Conant 1992 AIDS work.

Clinical TrialPMID: 7859140

Isolation of bovine thymin: a polypeptide hormone of the thymus.

Original ResearchPMID: 4128781

Treatment of active rheumatoid arthritis with slow intravenous injections of thymopentin. A double-blind placebo-controlled randomised study

Malaise and colleagues, The Lancet 1985 — the strongest rheumatology result thymopentin has, and one the page used to cite without saying what it found. Forty-one patients with active rheumatoid arthritis received 50 mg by slow intravenous injection three times weekly for three weeks. Thymopentin was significantly better than placebo at reducing tenderness, joint swelling, severity of pain on waking and overall disease activity. It is worth noting the route: this is the intravenous regimen the Italian label later carried for autoimmune indications, not the subcutaneous one usually quoted for the drug.

Clinical TrialPMID: 2858708

Thymopentin therapy reduces the clinical severity of atopic dermatitis

Leung DY and colleagues, Journal of Allergy and Clinical Immunology 1990. The landmark atopic dermatitis clinical study for thymopentin — reported reduced clinical severity of AD with TP-5 therapy, providing the principal historical basis for the atopic dermatitis indication in some non-U.S. markets. Later balanced by the Stiller 1994 JAAD placebo-controlled adjunctive study showing a significant improvement over placebo at 12 weeks, with the authors concluding thymopentin “may be a safe effective adjunct to therapy in patients with severe atopic dermatitis.”

Clinical TrialPMID: 2185294

Maintenance of CD4+ cells by thymopentin in asymptomatic HIV-infected subjects: results of a double-blind, placebo-controlled study

Clinical TrialPMID: 1361746

A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin.

Goldstein G, Scheid MP, Boyse EA, Schlesinger DH and Van Wauwe J, Science, 22 June 1979. The paper that created thymopentin. Having isolated the 49-residue thymopoietin, Gideon Goldstein's group synthesised residues 32-36 — arginyl-lysyl-aspartyl-valyl-tyrosine — and showed the fragment reproduced the parent hormone's signature pair of actions: it induced murine prothymocytes to differentiate into thymocytes while inhibiting differentiative induction of B-lineage cells, a combination the authors noted was "presently unique to the parent molecule thymopoietin." In vivo it also reduced the elevated autologous rosette-forming cells in the spleens of athymic mice. The closing suggestion — that the readily synthesised pentapeptide "might serve as a therapeutic substitute for thymopoietin" — is the origin of every clinical use the molecule later had.

Original ResearchPMID: 451537

Short in vitro half-life of thymopoietin32-36 pentapeptide in human plasma

Tischio JP, International Journal of Peptide and Protein Research 1979. Foundational pharmacokinetic paper characterizing the short plasma half-life of TP-5 — a key practical limitation that has constrained thymopentin's therapeutic translation throughout its commercial history.

Original ResearchPMID: 395119

Quick Facts

Class
Thymic Peptide
Tier
D
Evidence
Preliminary
Safety
Limited Data
Updated
Nov 2026
Citations
19PubMed

Also known as

TP-5Thymopoietin (32-36)Arg-Lys-Asp-Val-Tyr

Tags

Thymic PeptideImmunomodulatorPentapeptideHistorical

Peptide Families

Related Goals

Conditions Discussed

Evidence Score

Overall Confidence35%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.